Adverum Biotechnologies (ADVM) Announces $200M Common Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
Go back to Adverum Biotechnologies (ADVM) Announces $200M Common Share Offering
August 13, 2020 5:57 AM EDT
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) today announced the pricing of its underwritten public offering of 14,500,000 shares of its common stock at a public offering price of $13.00 per share. The company has granted the underwriters a 30-day option to purchase up to an additional... More
August 10, 2020 4:45 PM EDT
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced positive new interim data from Cohorts 1-4 of the OPTIC Phase 1 clinical trial of ADVM-022 intravitreal (IVT) injection gene therapy in patients requiring frequent anti-VEGF injections for their wet age-related macular degeneration (AMD). The company also reported recent business progress and... More
August 10, 2020 4:39 PM EDT
Adverum Biotechnologies (NASDAQ: ADVM) reported Q2 EPS of ($0.36), $0.08 worse than the analyst estimate of ($0.28).
Cash, cash equivalents and short-term investments were $280.1 million as of June 30, 2020, compared to $166.0 million as of December 31, 2019. Adverum expects this quarter-end cash position to fund operations into...
More
